VEGFA and hepatocellular carcinoma: This not only suggests that ICI/VEGF treatment is effective in non-viral HCC, demonstrating a favourable mOS taking in account historic comparators, but also that patients receiving sorafenib demonstrated unexpectedly durable response potentially related to the post-progression use of ICI, which, in turn, will have impacted the mOS hazard ratio for the non-viral HCC subgroup [112].